GSK's RSV vaccine succeeds in late-stage trial for older adults

The RSV vaccine is a key component of the British drugmaker's plans to boost its drug development success rate as it prepares to spin off its consumer health venture next month as an independent listed company called Haleon. GSK then aims to focus solely on vaccines and prescription drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IvWVHLd
via IFTTT